Amylyx Pharmaceuticals Inc (AMLX)
1.83
+0.01
(+0.55%)
USD |
NASDAQ |
May 16, 16:00
1.835
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals Net Income (Quarterly): -118.79M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -118.79M |
| December 31, 2023 | 4.731M |
| September 30, 2023 | 20.89M |
| June 30, 2023 | 22.07M |
| March 31, 2023 | 1.573M |
| December 31, 2022 | -42.70M |
| September 30, 2022 | -53.76M |
| Date | Value |
|---|---|
| June 30, 2022 | -54.07M |
| March 31, 2022 | -47.85M |
| December 31, 2021 | -28.34M |
| September 30, 2021 | -23.14M |
| June 30, 2021 | -21.92M |
| March 31, 2021 | -14.52M |
| December 31, 2020 | -8.592M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-118.79M
Minimum
Mar 2024
22.07M
Maximum
Jun 2023
-26.03M
Average
-22.53M
Median
Net Income (Quarterly) Benchmarks
| Cassava Sciences Inc | 25.04M |
| iRhythm Technologies Inc | -45.67M |
| Bristol-Myers Squibb Co | -11.91B |
| Moderna Inc | -1.175B |
| ACADIA Pharmaceuticals Inc | 16.56M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 88.64M |
| Total Expenses (Quarterly) | 210.77M |
| EPS Diluted (Quarterly) | -1.75 |
| Enterprise Value | -248.84M |
| Gross Profit Margin (Quarterly) | -31.32% |
| Profit Margin (Quarterly) | -134.0% |
| Earnings Yield | -58.47% |
| Normalized Earnings Yield | -58.47 |